Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Immunology, Immunotherapy
Published in: Cancer Immunology, Immunotherapy 11-12/2002

01-12-2002 | Original Article

41.8°C whole body hyperthermia as an adjunct to chemotherapy induces prolonged T cell activation in patients with various malignant diseases

Authors: Djordje Atanackovic, Axel Nierhaus, Michael Neumeier, Dieter K. Hossfeld, Susanna Hegewisch-Becker

Published in: Cancer Immunology, Immunotherapy | Issue 11-12/2002

Login to get access
Metadata
Title
41.8°C whole body hyperthermia as an adjunct to chemotherapy induces prolonged T cell activation in patients with various malignant diseases
Authors
Djordje Atanackovic
Axel Nierhaus
Michael Neumeier
Dieter K. Hossfeld
Susanna Hegewisch-Becker
Publication date
01-12-2002
Publisher
Springer-Verlag
Published in
Cancer Immunology, Immunotherapy / Issue 11-12/2002
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-002-0327-x

Other articles of this Issue 11-12/2002

Cancer Immunology, Immunotherapy 11-12/2002 Go to the issue

Original Article

The combination of a chemokine, cytokine and TCR-based T cell stimulus for effective gene therapy of cancer

Original Article

Phase I/II study of sequential chemoimmunotherapy (SCIT) for metastatic melanoma: outpatient treatment with dacarbazine, granulocyte-macrophage colony-stimulating factor, low-dose interleukin-2, and interferon-alpha

Original Article

Calcitonin-specific antitumor immunity in medullary thyroid carcinoma following dendritic cell vaccination

Review

Adjuvant immunotherapy for solid tumors: from promise to clinical application

Original Article

Mucin gene (MUC1) transfected dendritic cells as vaccine: results of a phase I/II clinical trial

Original Article

Analysis of the antibody repertoire of lymphoma patients
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits